Trump picks Heidi Overton for FDA as White House health agenda moves directly into regulator
By Maya Oliver I SCN NEWS
WASHINGTON — President Donald Trump has nominated White House health-policy aide Dr. Heidi Overton to lead the Food and Drug Administration, choosing a physician already deeply involved in his administration's health agenda to take control of one of America's most powerful regulators after months of leadership turmoil and extensive staff losses.
The nomination requires Senate confirmation.
Trump announced his choice Wednesday, describing Overton as a trusted member of his policy team who would advance priorities including faster medical innovation, clinical-trial reform and lower prescription-drug prices.
But the significance of the selection extends beyond another change at the top of the FDA.
Overton currently serves as deputy director of the White House Domestic Policy Council, placing her inside the operation developing Trump's health policies rather than inside the FDA bureaucracy responsible for implementing and regulating them.
If confirmed, she would therefore move directly from helping shape White House policy into control of the agency responsible for deciding whether medicines, vaccines and medical devices reach American patients and under what conditions.
That could create a much tighter connection between presidential health priorities and FDA decision-making.
An FDA already transformed
Overton would inherit an agency considerably different from the institution Trump entered office with.
Reuters reports the FDA has lost more than 3,000 employees during the past year, including senior officials and division leaders, amid restructuring and departures that have raised concerns about institutional expertise and stability.
She would replace former Commissioner Marty Makary, who resigned in May after approximately 13 months in the job.
Makary's tenure included clashes involving vaping regulation, pharmaceutical companies and internal management. Acting Commissioner Kyle Diamantas has led the agency since his departure.
The combination makes Overton's nomination more consequential than a routine leadership transition.
She would be taking control after both substantial personnel losses and unusually rapid turnover at the top.
From White House policymaker to regulator
Overton is a physician who earned her medical degree from the University of New Mexico and later received advanced training at Johns Hopkins University, including a doctorate in clinical investigation.
Before joining Trump's second administration, she served as chief policy officer at the conservative America First Policy Institute.
Inside the White House, however, her role has gone substantially beyond providing medical advice.
She has worked with Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services Administrator Mehmet Oz on major administration health initiatives.
That includes prescription-drug pricing.
In October 2025, Kennedy publicly credited Overton and several other officials with playing important roles in negotiations surrounding a White House drug-pricing agreement.
More recently, she was involved with Trump's effort to reshape childhood vaccine recommendations.
Overton appeared at the White House when Trump signed an executive order this month directing changes to vaccine policy, including consideration of separating the combined measles, mumps and rubella vaccine into individual shots.
That policy has drawn criticism from parts of the medical establishment and is likely to become an important subject during her Senate confirmation process.
Three competing forces inside Trump health policy
Overton would also enter a complicated political environment.
Trump has generally pushed for deregulation, faster approvals and policies designed to encourage American pharmaceutical and biotechnology development.
Kennedy has brought a different emphasis to HHS, including skepticism toward pharmaceutical companies and major changes to federal vaccine policy.
Traditional Republican lawmakers and pharmaceutical-industry interests bring still another set of priorities.
AP reports Overton could consequently find herself balancing Trump's deregulatory agenda, Kennedy's more populist and corporate-skeptical approach and Republican concerns about how far the administration should reshape FDA regulation.
Her advantage may be that she has already been operating where those competing priorities meet: the White House.
Senate confirmation could focus heavily on vaccines
Overton's confirmation is unlikely to revolve exclusively around administrative experience.
Vaccines could become one of the defining issues.
Trump's administration has pursued significant changes to childhood vaccine policy, while some Republican lawmakers — including Senate health committee chairman Bill Cassidy, a physician — have previously raised concerns over elements of the administration's vaccine approach.
The FDA commissioner's authority makes those disagreements particularly important.
The agency regulates vaccines themselves, evaluates clinical evidence and plays a central role in determining which medical products can be marketed in the United States.
Overton could also face questioning about abortion medication.
Before joining the White House, she wrote critically about expanded access to mifepristone, the medication widely used for abortion, while working at America First Policy Institute.
That issue has repeatedly placed the FDA at the centre of national legal and political disputes.
The deeper institutional change
Every administration selects FDA commissioners who broadly share its health-policy philosophy.
What makes Overton's selection noteworthy is how directly she comes from the White House machinery already designing the policies the FDA may be asked to execute.
Trump isn't bringing in an outside academic or promoting a longtime FDA official.
He is moving one of his own domestic-policy officials into the regulator.
And she would arrive after a period in which thousands of employees have left the agency and senior leadership has repeatedly changed.
That combination could give the incoming commissioner unusual influence over rebuilding the FDA's personnel, regulatory philosophy and relationship with the White House.
It also creates the central question likely to follow Overton through confirmation:
Will she rebuild FDA independence after a turbulent year, or make the agency more directly responsive to the administration's health agenda?
Her record provides evidence for why that question matters.
Overton has already worked on drug pricing, health regulation and vaccine policy from inside Trump's White House.
If the Senate confirms her, she will move from helping design those policies to running the federal agency responsible for making some of their most consequential scientific and regulatory decisions.
That makes Trump's choice more than another personnel announcement.
It potentially moves the centre of Trump's health-policy operation directly into the FDA.